News

A lot of people with Charcot-Marie-Tooth (CMT) disease have surgery to correct foot deformities, a British study reports. Another important finding was that an operation requires a number of individual surgical procedures but few surgeons use the same pattern of procedures for the same type of operation. The study,  “…

Researchers have uncovered how mutations in the peripheral myelin protein P2 — recently linked to the development of Charcot-Marie-Tooth (CMT) disease — might impact myelin formation to cause the disease. P2 is part of the myelin sheath, where it acts to transfer fatty acids to and from nerve cell membranes…

Acceleron Pharma has launched a Phase 2 clinical trial (NCT03124459) to investigate the safety and effectiveness of its product ACE-083 as a potential treatment for Charcot-Marie-Tooth disease (CMT). The first patient already has been dosed, the company announced. “People diagnosed with CMT currently have no drug therapy options…

French researchers have identified two novel mutations occurring within the NEFH gene that led tof a hereditary form of Charcot-Marie-Tooth disease in two families. Their study, “Cryptic amyloidogenic elements in mutant NEFH causing Charcot-Marie-Tooth 2 trigger aggresome formation and neuronal death,” appeared in the journal Acta Neuropathologica Communications.

Researchers have identified molecular abnormalities in cells found during embryonic nerve development that are common to patients with demyelinating Charcot–Marie–Tooth (CMT) disease caused by three different mutations. The findings advance the understanding of how the disease develops, and “further studies focusing on the common molecular signature in demyelinating CMT could reveal a…

Charcot–Marie–Tooth (CMT) disease type 2, or axonal CMT, has long been associated with genetic variants of the MFN2 gene, which encodes a protein of the mitochondrial outer membrane. A Japanese study now finds that these mutations may also be related to demyelinating CMT subtype (type 1), which could help explain the different clinical…

Pharnext presented updates on its Phase 3 PLEO-CMT trial (NCT02579759) evaluating its investigative product PXT3003 as a potential treatment for Charcot-Marie-Tooth type 1A disease (CMT1A) at the 2017 Peripheral Nerve Society Meeting, July 8-12 in Barcelona, Spain. Data was orally presented by the company’s chief medical…

Researchers have identified MCM3AP as a gene involved in the development of a childhood-onset version of the neurological disorder Charcot-Marie-Tooth disease. The study, “MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability,” was published in the journal Brain. Charcot-Marie-Tooth disease (CMT) is a group of hereditary neuropathies, or diseases affecting…

Routine exercise done at a patient’s own pace improves strength and lessens disability in patients with Charcot-Marie-Tooth (CMT) disease, reports a Canadian study that compared patients adhering to a “self-directed” exercise program with those who do not exercise. The study, “Effects of Self-Selected Exercise on Strength in Charcot–Marie–Tooth Disease…

Flex Pharma announced that its upcoming Phase 2 COMMIT trial investigating the effects of FLX-787 in patients with cramps associated with Charcot-Marie-Tooth (CMT) disease is approved by the Inherited Neuropathies Consortium (INC). The INC is composed of academic medical centers, organizations for patient support and research resources focused…